Neurological Adverse Events to Voriconazole: Evidence for Therapeutic Drug Monitoring

A. Imhof*, D.J. Schaer, M. Schneemann, R. Laffer, U. Schanz.

Author address: 

Department of Internal Medicine University Hospital ZUrich, 8091 ZUrich, Switzerland


Background: Treatment with voriconazoLe (VOR), a broad-spectrum second-generation azoLe antifungaL agent, has been shown to result in favorable outcomes in the setting of muLtipLe opportunistic fungaL infections. VOR has a considerable interpatient variation of serum concentrations, and recent observations suggest that adverse events might be close related. Objectives: Association of VOR serum Level increase (sVL) with severe neuroLogicaL adverse eve n ts. Methods E Results: In a retrospective analysis of 28 treatment courses, 6 patients presented with neuroLogicaL adverse events (nAE, haLLucination, encephaLopathy, and visual disturbance). OR per 0.1 pg/mL sVL was 2.34, (95% CI: 1.54-3.55, p

abstract No: 


Full conference title: 

14th International Symposium of Infections in the Immunocompromised Host
    • ISIIH, 14th